Jörg Hüser studied Biology at the Ruhr-University in Bochum, Germany. He received a PhD in Physiology working on excitation-contraction coupling in cardiac muscle cells. Following a postdoctural training at Loyola University in Chicago, Stritch School of Medicine, in Maywood, IL, USA, he joined Bayer AG’s Pharma Research in Wuppertal, Germany. During his almost 25 year tenure at Bayer, he held different management positions, leading research units in Lead Discovery and Heart & Vascular Disease Research. In June 2023 he joined Axxam as Chief Scientific Officer.
Beyond Function Only: Native Molecule Binding Assays Using Affinity-Selection Mass Spectrometry (ASMS)
13 February, 16.00 CET
Momentum Biotechnologies and Axxam have recently joined forces to combine the AXXDiversity small molecule library with Momentum’s Affinity Ligand Identification System (ALIS) as a new screening option for our clients. The platform enables identification of small molecule binders to protein or nucleic acid targets. This field is continuously gaining relevance in the context of bifunctional degraders, molecular glues, RNA targets, and protein-protein interactions.
The webinar will briefly describe main features of the Axxam compound library and introduce Momentum’s ALIS and its underlying simple, automated, and high-throughput workflow utilizing Affinity Selection Mass Spectroscopy (ASMS). Advantages of this methodology over other drug target binding assay methods include minimal target quantity and assay development requirements, protocol flexibility, and target versatility. Primary hits are immediately identified and available for further validation and follow-up studies, for which Axxam can add further assay biology and early medicinal chemistry support.
Interaction assays; High-throughput screening; Hit validation; TR-FRET; Fluorescence polarization; Generative Machine Learning; Virtual Screening; Virtual High-Throughput Screening; Library Design.
Jörg Hüser, CSO, Axxam
- Can Ozbal, CEO, Momentum Biotechnologies
Having earned an A.B. in Chemistry from Bowdoin College and a Ph.D. in Toxicology from M.I.T, Can Ozbal joined the M.I.T. faculty as an Instructor. After a brief stint in academics, he joined BioTrove where he was part of the team that developed and commercialized the RapidFire high-throughput mass spectrometry system. This business unit was spun out as Biocius Life Sciences upon the acquisition of BioTrove by Life Technologies where Can was the COO. Biocius was in turn acquired by Agilent Technologies after which Can moved on to start PureHoney Technologies as a CRO offering mass spectrometry-based bioanalytical services. PureHoney was rebranded as Momentum Biotechnologies after an investment from Care Equity in early 2023.